CHMX
NEXT-ChemX Corporation0.0111
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
316.87KP/E (TTM)
-Basic EPS (TTM)
-0.06Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
NEXT-ChemX posted a Q2 net loss of $455,639, up 19% y/y from $383,379, driven by higher interest expense on deferred debt and legal fees, while operating expenses dipped 11% y/y to $391,584 on reduced contractor payments. For the half-year, the net loss narrowed slightly to $921,565 from $939,787 y/y, with operating cash use improving to $535,506 from $861,765, funded by $495,000 in new convertible notes. Cash dwindled to $22,041 amid $2.1M non-current notes and $845,000 loans, yet prepaid assets for pilot plant work held at $635,041. The iTDE tech pilot nears Q3 completion in India for lithium extraction demos. Ongoing Texas court appeal over share turnover adds uncertainty.
10-Q
Q1 FY2025 results
NEXT-ChemX posted a narrower Q1 2025 net loss of $465,926, down 16.4% y/y from $556,408, as operating expenses fell 20.2% y/y to $414,762 on reduced salaries and no accrued leave, while interest expense climbed to $63,965. The operating loss of $414,762 narrowed y/y, but net loss exceeded it by $51,164 due to interest. Diluted EPS held at $(0.02) on 28,546,834 shares, consistent with the prior year. Cash dwindled to $612 from $62,547 at year-end, with operating cash use at $206,935 offset by $145,000 in financing; total debt stood at $2,575,004 including $845,000 current loans at 10% and $1,730,004 convertible notes. Pilot plants near completion for lithium extraction demos. Ongoing Texas court appeal over share turnover adds uncertainty.
10-K
FY2024 results
NEXT-ChemX Corporation narrowed its FY2024 net loss to $1.8 million from $2.5 million in 2023, driven by slashed operating expenses amid zero revenues and ongoing iTDE technology development for lithium extraction. Q4 saw $1.6 million in Series F convertible notes raised, bolstering liquidity despite a $3.9 million working capital deficit, while deferred employee salaries and extended shareholder loans sustained operations. Progress accelerated with a $340,000 research grant to BITS Pilani in Q4, targeting pilot system completion by Q3 2025, yet funding shortages slowed momentum. Debt restructuring hangs over quarterly cash flows. Cybersecurity threats loom large, risking tech theft and deployment delays.
10-Q
Q3 FY2024 results
Next-ChemX posted a Q3 net loss of $354,495, narrower than the $922,857 loss a year earlier, while nine-month losses eased to $1,219,391 from $1,778,554, thanks to lower general and administrative expenses of $319,441 versus $403,435 y/y and $1,163,868 versus $1,421,663 y/y. No revenue yet, as pilot plants for the iTDE lithium extraction tech undergo trials in India, with customer brine testing eyed for Q1 2025. Cash stood at $35,386 on September 30, 2024, up from $2,458 year-end, bolstered by $1,066,000 in financing including $1,220,004 in new convertible notes, yet operating cash burn hit $1,033,072 over nine months. Total liabilities climbed to $5,702,132, driven by accrued payroll and shareholder loans, while the $3,150,114 intangible asset faces potential restatement from ongoing audit review. Ongoing Texas court battles over share transfers pose a key risk.
IPO
Website
Employees
Sector
Industry
ALB
Albemarle Corporation
131.07-1.15
ATLX
Atlas Lithium Corporation
4.03+0.19
BKTH
Breakthrough Chemistry Inc.
0.17+0.00
CETY
Clean Energy Technologies, Inc.
0.98+0.03
CVAT
Cavitation Technologies, Inc.
0.05-0.01
NEWH
NewHydrogen Inc.
0.02+0.00
NMGX
NANO MAGIC INC.
0.25-0.02
NXTT
Next Technology Holding Inc.
6.73-0.17
SQM
Sociedad Quimica y Minera S.A.
64.17-0.80
XCH
XCHG Limited
1.13-0.07